SynthesisBMC infectious diseases2026
Antimicrobial resistance among clinical Enterobacterales isolated from humans in Senegal: a systematic review and meta-analysis from 1987 to 2022.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mitigation of antimicrobial resistance (AMR) has become a priority in every part of the world. Understanding AMR dynamics in Senegal is crucial for updating empirical antimicrobial treatments, adapting public health policies, and guiding future research. Therefore, this study conducted a systematic review and meta-analysis of clinical Enterobacterales resistance to 15 antimicrobials, determine AMR trends, and report the genetic determinants of AMR reported in Enterobacterales strains isolated from humans in Senegal over the past four decades.
methodsThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA 2020) were used and the protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database with registration number (CRD420251007413). Data analyses were conducted using Stata software, version 17.0, and consisted of a random-effects model analysis to estimate pooled AMR rates, publication bias assessments, and meta-regression analysis.
resultsThirty-nine research articles met the inclusion criteria and were selected for this study. A total of 7911 Enterobacterales strains were studied. These strains were isolated between 1987 and 2022, mainly from urine [23 studies; 61% (95% CI: 45, 74)], blood [15 studies; 39% (95% CI: 26, 55)], and stool [15 studies; 39% (95% CI: 26, 55)]. The overall pooled AMR rates ranged from 3% (95% CI: 1, 5) for carbapenems to 66% (95% CI: 53, 77) for trimethoprim-sulfamethoxazole (SXT). Drastic upward trends were reported for all 15 antimicrobials tested, except for amikacin, chloramphenicol, and tetracycline, for which stable AMR trends were observed. The Klebsiella isolates presented the highest AMR rates, followed by E. coli, Shigella, and Salmonella isolates. Genetic determinants of resistance to beta-lactams, fluoroquinolones, aminoglycosides, trimethoprim, macrolides, nucleoside antibiotics, and tetracycline were reported in Senegal. In addition, class 1 and 2 integrons were reported and carried mostly aadA1, aadA2, dfrA7, dfrA1, and sat as cassettes.
conclusionsCarbapenems, amikacin, fosfomycin, and chloramphenicol could be considered good for the treatment of severe infections. In addition, there is a need to adjust empirical antimicrobial treatment guidelines in Senegal and implement whole-genome sequencing-based surveillance methods. Recommendations should include the implementation of prevention and infection control policies and the exploration of alternative therapies. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.